nach oben

Current Oncology Reports

Erschienen in:

01.05.2016 | Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)

Improving Systemic Chemotherapy for Bladder Cancer

verfasst von: Tracy L. Rose, Matthew I. Milowsky

Erschienen in: Current Oncology Reports | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Systemic chemotherapy is integral to the management of muscle-invasive and metastatic bladder cancer (BCa). Neoadjuvant chemotherapy has been increasingly utilized for muscle-invasive BCa over the past several years, and several options for cisplatin-based regimens have emerged. Adjuvant chemotherapy may be considered for select patients who did not receive neoadjuvant therapy. Systemic chemotherapy added to radiotherapy is a critical component of a bladder-preserving approach and superior to radiotherapy alone. Cisplatin-based chemotherapy has been the mainstay for metastatic BCa for more than three decades. Novel targeted agents are in development fueled by the recent molecular characterization of BCa. Recent trials of immunotherapy have demonstrated the possibility of a less toxic and potentially more effective treatment for metastatic disease. It is an extremely exciting time for BCa research, and much needed improvements in systemic treatment are most certainly on the horizon.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.21254.CrossRefPubMed

Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374(9685):239–49. doi:10.1016/s0140-6736(09)60491-8.CrossRefPubMed

Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66. doi:10.1056/NEJMoa022148.CrossRefPubMed

Sonpavde G, Goldman BH, Speights VO, Lerner SP, Wood DP, Vogelzang NJ, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009;115(18):4104–9. doi:10.1002/cncr.24466.CrossRefPubMedPubMedCentral

Rosenblatt R, Sherif A, Rintala E, Wahlqvist R, Ullen A, Nilsson S, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol. 2012;61(6):1229–38. doi:10.1016/j.eururo.2011.12.010.CrossRefPubMed

Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet. 1999;354(9178):533-40.

Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16):2171–7. doi:10.1200/jco.2010.32.3139.CrossRefPubMed

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. European urology. 2005;48(2):202-5; discussion 5-6. doi:10.1016/j.eururo.2005.04.006.

Dash A, Pettus JA, Herr HW, Bochner BH, Dalbagni G, Donat SM, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008;113(9):2471–7. doi:10.1002/cncr.23848.CrossRefPubMedPubMedCentral

10.

Yeshchina O, Badalato GM, Wosnitzer MS, Hruby G, RoyChoudhury A, Benson MC, et al. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. Urology. 2012;79(2):384–90. doi:10.1016/j.urology.2011.10.050.CrossRefPubMed

11.

Balar AV, Iyer G, Milowsky MI, Huang WC, Woods M, Donat SM, et al. Multicenter prospective phase II trial of neoadjuvant (neo) dose dense gemcitabine and cisplatin (DD-GC) in patients (pts) with muscle-invasive bladder cancer (MIBC). ASCO Meeting Abstracts. 2016;34:436.

12.

von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–8. doi:10.1200/jco.2005.07.757.CrossRefPubMed

13.

von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–77.PubMed

14.••

Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015. doi:10.1002/cncr.29387. There is no difference in pathologic complete response between neoadjuvant GC and MVAC chemotherapy.

15.

Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015;67(2):241–9. doi:10.1016/j.eururo.2014.09.007.CrossRefPubMedPubMedCentral

16.••

Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014;32(18):1889–94. doi:10.1200/jco.2013.52.4785. Neoadjuvant dose-dense MVAC is well-tolerated and results in significant pathologic downstaging with 49% of patients achieving <pT2.

17.••

Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014;32(18):1895–901. doi:10.1200/jco.2013.53.2465. Neoadjuvant accelerated MVAC is well-tolerated and results in significant pathologic downstaging with 38% of patients achieving pT0.

18.

Plimack ER, Hoffman-Censits JH, Kutikov A, Greenberg RE, Bilusic M, Chen DYT, et al. Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients (pts) with muscle-invasive bladder cancer (MIBC): final results of a multicenter phase II study. ASCO Meeting Abstracts. 2014;32(15_suppl):4513.

19.

Smith SC, Baras AS, Lee JK, Theodorescu D. The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res. 2010;70(5):1753–8. doi:10.1158/0008-5472.can-09-3562.CrossRefPubMedPubMedCentral

20.

David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol. 2007;178(2):451–4. doi:10.1016/j.juro.2007.03.101.CrossRefPubMed

21.

Zaid HB, Patel SG, Stimson CJ, Resnick MJ, Cookson MS, Barocas DA, et al. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Urology. 2014;83(1):75–80. doi:10.1016/j.urology.2013.07.072.CrossRefPubMed

22.

Reardon ZD, Patel SG, Zaid HB, Stimson CJ, Resnick MJ, Keegan KA, et al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur Urol. 2014. doi:10.1016/j.eururo.2014.01.009.PubMedPubMedCentral

23.

Cognetti F, Ruggeri EM, Felici A, Gallucci M, Muto G, Pollera CF, et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol. 2012;23(3):695–700. doi:10.1093/annonc/mdr354.CrossRefPubMed

24.

Stockle M, Meyenburg W, Wellek S, Voges G, Gertenbach U, Thuroff JW, et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol. 1992;148(2 Pt 1):302–6. discussion 6-7.PubMed

25.

Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991;145(3):459–64. discussion 64-7.PubMed

26.

Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. European Urology. 2005;48(2):189-99; discussion 99-201. doi:10.1016/j.eururo.2005.04.005.

27.

Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014;66(1):42–54. doi:10.1016/j.eururo.2013.08.033.CrossRefPubMed

28.

Paz-Ares LG, Solsona E, Esteban E, Saez A, Gonzalez-Larriba J, Anton A, et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. ASCO Meeting Abstracts. 2010;28(18_suppl):LBA4518.

29.••

Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015;16(1):76–86. doi:10.1016/s1470-2045(14)71160-x. There was no survival benefit of immediate over deferred chemotherapy for patients with high-risk MIBC after radical cystectomy. This study was underpowered and did not meet goal of accrual.

30.

Galsky MD, Stensland K, Moshier EL, Sfakianos J, McBride RB, Tsao C-K, et al. Effectiveness of adjuvant chemotherapy (AC) versus observation in patients with >= pT3 and/or pN+ bladder cancer (BCa). ASCO Meeting Abstracts. 2015;33(15_suppl):4517.

31.

Shipley WU, Prout Jr GR, Einstein AB, Coombs LJ, Wajsman Z, Soloway MS, et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. Jama. 1987;258(7):931–5.CrossRefPubMed

32.

Housset M, Maulard C, Chretien Y, Dufour B, Delanian S, Huart J, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol. 1993;11(11):2150–7.PubMed

33.

Sauer R, Dunst J, Altendorf-Hofmann A, Fischer H, Bornhof C, Schrott KM. Radiotherapy with and without cisplatin in bladder cancer. Int J Radiat Oncol Biol Phys. 1990;19(3):687–91.CrossRefPubMed

34.

Shipley WU, Kaufman DS, Zehr E, Heney NM, Lane SC, Thakral HK, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology. 2002;60(1):62–7. discussion 7-8.CrossRefPubMed

35.

Weiss C, Engehausen DG, Krause FS, Papadopoulos T, Dunst J, Sauer R, et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys. 2007;68(4):1072–80. doi:10.1016/j.ijrobp.2007.01.054.CrossRefPubMed

36.

Chung PW, Bristow RG, Milosevic MF, Yi QL, Jewett MA, Warde PR, et al. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol. 2007;25(4):303–9. doi:10.1016/j.urolonc.2006.09.015.CrossRefPubMed

37.

Rodel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20(14):3061–71.CrossRefPubMed

38.

Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace 3rd HJ, Toonkel LM, et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 2009;73(4):833–7. doi:10.1016/j.urology.2008.09.036.CrossRefPubMed

39.

Rodel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol. 2006;24(35):5536–44. doi:10.1200/jco.2006.07.6729.CrossRefPubMed

40.

James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477–88. doi:10.1056/NEJMoa1106106.CrossRefPubMed

41.

Oh KS, Soto DE, Smith DC, Montie JE, Lee CT, Sandler HM. Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys. 2009;74(2):511–7. doi:10.1016/j.ijrobp.2008.08.021.CrossRefPubMed

42.

Patel B, Forman J, Fontana J, Frazier A, Pontes E, Vaishampayan U. A single institution experience with concurrent capecitabine and radiation therapy in weak and/or elderly patients with urothelial cancer. Int J Radiat Oncol Biol Phys. 2005;62(5):1332–8. doi:10.1016/j.ijrobp.2005.01.004.CrossRefPubMed

43.

Dunst J, Weigel C, Heynemann H, Becker A. Preliminary results of simultaneous radiochemotherapy with paclitaxel for urinary bladder cancer. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]. 1999;175 Suppl 3:7–10.CrossRef

44.

Nichols Jr RC, Sweetser MG, Mahmood SK, Malamud FC, Dunn NP, Adams JP, et al. Radiation therapy and concomitant paclitaxel/carboplatin chemotherapy for muscle invasive transitional cell carcinoma of the bladder: a well-tolerated combination. International journal of cancer Journal international du cancer. 2000;90(5):281–6.CrossRefPubMed

45.

Adamo V, Magno C, Spitaleri G, Garipoli C, Maisano C, Alafaci E, et al. Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen. Oncology. 2005;69(5):391–8. doi:10.1159/000089993.CrossRefPubMed

46.

Soto Parra H, Cavina R, Latteri F, Sala A, Dambrosio M, Antonelli G, et al. Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study. Ann Oncol. 2002;13(7):1080–6.CrossRefPubMed

47.

Hussain SA, Palmer DH, Lloyd B, Collins SI, Barton D, Ansari J, et al. A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. Oncology letters. 2012;3(4):855–9. doi:10.3892/ol.2012.563.PubMedPubMedCentral

48.

Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. European journal of cancer (Oxford, England : 1990). 2006;42(1):50–4.CrossRef

49.

Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012;30(10):1107–13. doi:10.1200/jco.2011.38.6979.CrossRefPubMedPubMedCentral

50.

Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol. 2011;29(12):1525–30. doi:10.1200/jco.2010.31.6067.CrossRefPubMed

51.

Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer. 2004;100(8):1639–45. doi:10.1002/cncr.20123.CrossRefPubMed

52.

Dogliotti L, Carteni G, Siena S, Bertetto O, Martoni A, Bono A, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007;52(1):134–41. doi:10.1016/j.eururo.2006.12.029.CrossRefPubMed

53.

Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 2012;23(2):406–10. doi:10.1093/annonc/mdr156.CrossRefPubMed

54.

De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30(2):191–9. doi:10.1200/jco.2011.37.3571.CrossRefPubMedPubMedCentral

55.

Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107(3):506–13. doi:10.1002/cncr.22031.CrossRefPubMed

56.

Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432–8. doi:10.1200/jco.2011.34.8433.CrossRefPubMed

57.

Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454–61. doi:10.1200/jco.2008.20.5534.CrossRefPubMed

58.

Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17(10):3173–81.PubMed

59.

Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Choueiri TK, Necchi A, et al. Improved 5-factor prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma. J Urol. 2015. doi:10.1016/j.juro.2015.07.111.

60.

Papamichael D, Gallagher CJ, Oliver RT, Johnson PW, Waxman J. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer. 1997;75(4):606–7.CrossRefPubMedPubMedCentral

61.

Joly F, Houede N, Noal S, Chevreau C, Priou F, Chinet-Charrot P, et al. Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study. Clin Genitourin Cancer. 2009;7(2):E28–33. doi:10.3816/CGC.2009.n.018.CrossRefPubMed

62.

Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol. 2002;20(4):937–40.CrossRefPubMed

63.

McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997;15(5):1853–7.PubMed

64.

Choueiri TK, Ross RW, Jacobus S, Vaishampayan U, Yu EY, Quinn DI, et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol. 2012;30(5):507–12. doi:10.1200/jco.2011.37.7002.CrossRefPubMedPubMedCentral

65.

Witte RS, Elson P, Bono B, Knop R, Richardson RR, Dreicer R, et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol. 1997;15(2):589–93.PubMed

66.

Lorusso V, Pollera CF, Antimi M, Luporini G, Gridelli C, Frassineti GL, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. European journal of cancer (Oxford, England : 1990). 1998;34(8):1208–12.CrossRef

67.

Ko YJ, Canil CM, Mukherjee SD, Winquist E, Elser C, Eisen A, et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol. 2013;14(8):769–76. doi:10.1016/s1470-2045(13)70162-1.CrossRefPubMed

68.

Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006;24(21):3451–7. doi:10.1200/jco.2005.03.6699.CrossRefPubMed

69.

Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs. 2007;25(3):265–70. doi:10.1007/s10637-006-9020-9.CrossRefPubMed

70.

Witte RS, Manola J, Burch PA, Kuzel T, Weinshel EL, Loehrer Sr PJ. Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial. Invest New Drugs. 1998;16(2):191–5.CrossRefPubMed

71.

Culine S, Theodore C, De Santis M, Bui B, Demkow T, Lorenz J, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer. 2006;94(10):1395–401. doi:10.1038/sj.bjc.6603118.CrossRefPubMedPubMedCentral

72.

Vaughn DJ, Srinivas S, Stadler WM, Pili R, Petrylak D, Sternberg CN, et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer. 2009;115(18):4110–7. doi:10.1002/cncr.24460.CrossRefPubMed

73.

Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer. 2001;92:2993–8.

74.

Pectasides D, Aravantinos G, Kalofonos H, Kiamouris C, Bafaloukos D, Xiros N, et al. Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. Annals of oncology: official journal of the European Society for Medic al Oncology/ESMO. 2001;12:1417–22.

75.

Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol. 2010;11(9):861–70. doi:10.1016/s1470-2045(10)70086-3.CrossRefPubMed

76.

Bambury RM, Benjamin DJ, Chaim JL, Zabor EC, Sullivan J, Garcia-Grossman IR, et al. The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience. Oncologist. 2015;20(5):508–15. doi:10.1634/theoncologist.2014-0354.CrossRefPubMed

77.

Sonpavde G, Pond GR, Choueiri TK, Mullane S, Niegisch G, Albers P, et al. Single-agent taxane versus taxane-containing combination chemotherapy as salvage therapy for advanced urothelial carcinoma. Eur Urol. 2015. doi:10.1016/j.eururo.2015.07.042.

78.••

Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315-22. doi:10.1038/nature12965. Integrated analysis of 131 urothelial carcinoma tumors demonstrating that 69% of tumors have potentially actionable molecular alterations

79.

Petrylak DP, Tangen CM, Van Veldhuizen Jr PJ, Goodwin JW, Twardowski PW, Atkins JN, et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int. 2010;105(3):317–21. doi:10.1111/j.1464-410X.2009.08799.x.CrossRefPubMed

80.

Pruthi RS, Nielsen M, Heathcote S, Wallen EM, Rathmell WK, Godley P, et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int. 2010;106(3):349–54. doi:10.1111/j.1464-410X.2009.09101.x.CrossRefPubMed

81.

Wulfing C, Machiels JP, Richel DJ, Grimm MO, Treiber U, De Groot MR, et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer. 2009;115(13):2881–90. doi:10.1002/cncr.24337.CrossRefPubMed

82.

Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol. 2012;30(28):3545–51. doi:10.1200/jco.2012.41.9572.CrossRefPubMedPubMedCentral

83.

Hussain M, Daignault S, Agarwal N, Grivas PD, Siefker-Radtke AO, Puzanov I, et al. A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer. 2014;120(17):2684–93. doi:10.1002/cncr.28767.CrossRefPubMedPubMedCentral

84.

Junker K, van Oers JM, Zwarthoff EC, Kania I, Schubert J, Hartmann A. Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. Neoplasia. 2008;10(1):1–7.CrossRefPubMedPubMedCentral

85.

Gallagher DJ, Milowsky MI, Gerst SR, Ishill N, Riches J, Regazzi A, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol. 2010;28(8):1373–9. doi:10.1200/jco.2009.25.3922.CrossRefPubMed

86.

Bellmunt J, Gonzalez-Larriba JL, Prior C, Maroto P, Carles J, Castellano D, et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol. 2011;22(12):2646–53. doi:10.1093/annonc/mdr023.CrossRefPubMed

87.

Sridhar SS, Winquist E, Eisen A, Hotte SJ, McWhirter E, Tannock IF, et al. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs. 2011;29(5):1045–9. doi:10.1007/s10637-010-9408-4.CrossRefPubMed

88.

Dreicer R, Li H, Stein M, DiPaola R, Eleff M, Roth BJ, et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer. 2009;115(18):4090–5. doi:10.1002/cncr.24467.CrossRefPubMedPubMedCentral

89.

Necchi A, Mariani L, Zaffaroni N, Schwartz LH, Giannatempo P, Crippa F, et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol. 2012;13(8):810–6. doi:10.1016/s1470-2045(12)70294-2.CrossRefPubMed

90.

Petrylak D, Tagawa ST, Kohl M, Eisen A, Canil CM, Sridhar SS et al. Three-arm phase II randomized trial of docetaxel monotherapy or combined with ramucirumab or icrucumab in second-line locally advanced or metastatic urothelial carcinoma. Abstract 2508 (Presented at European Cancer Congress 2015).

91.

Seront E, Rottey S, Sautois B, Kerger J, D’Hondt LA, Verschaeve V, et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol. 2012;23(10):2663–70. doi:10.1093/annonc/mds057.CrossRefPubMed

92.

Milowsky MI, Iyer G, Regazzi AM, Al-Ahmadie H, Gerst SR, Ostrovnaya I, et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int. 2013;112(4):462–70. doi:10.1111/j.1464-410X.2012.11720.x.CrossRefPubMedPubMedCentral

93.

Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer discovery. 2014;4(5):546–53. doi:10.1158/2159-8290.cd-13-0353.CrossRefPubMedPubMedCentral

94.

Quinn DI, Ruel N, Twardowski P, Groshen SG, Dorff TB, Pal SK, et al. Eribulin in advanced urothelial cancer (AUC) patients (pts): a California Cancer Consortium trial—NCI/CTEP 7435. ASCO Meeting Abstracts. 2015;33(15_suppl):4504.

95.

Herbst RS, Gordon MS, Fine GD, Sosman JA, Soria J-C, Hamid O et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. ASCO Meeting Abstracts. 2013;31(15_suppl):3000.

96.••

Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–62. doi:10.1038/nature13904. Anti-PD-L1 MPDL3280 has activity in metastatic bladder cancer with several durable responses in a phase I study.

97.

Petrylak DP, Powles T, Bellmunt J, Braiteh FS, Loriot Y, Cruz Zambrano C, et al. A phase Ia study of MPDL3280A (anti-PDL1): updated response and survival data in urothelial bladder cancer (UBC). ASCO Meeting Abstracts. 2015;33(15_suppl):4501.

98.

Plimack ER, Bellmunt J, Gupta S, Berger R, Montgomery RB, Heath K, et al. Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012. ASCO Meeting Abstracts. 2015;33(15_suppl):4502.

99.

Galsky MD, Hahn NM, Albany C, Fleming MT, Starodub A, Twardowski P, et al. Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer. ASCO Meeting Abstracts. 2016;34:357.

100.

Hajdenberg J, Landau D, Vaena DA, Fishman MN, Rosser CJ, Milhem MM, et al. Early outcome results of a phase I/II study for an IL-2/T-cell receptor fusion protein in combination with gemcitabine and cisplatin (GC) in patients with locally advanced or metastatic urothelial cancer. ASCO Meeting Abstracts. 2012;30(15_suppl):e15010.

101.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–99. doi:10.1056/NEJMoa1406498.CrossRefPubMedPubMedCentral

102.

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21. doi:10.1038/nature12477.CrossRefPubMedPubMedCentral

103.••

Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A. 2014;111(8):3110–5. doi:10.1073/pnas.1318376111. There are molecular subtypes of bladder cancer that resemble the subtypes of breast cancer including “basal” and “luminal” subtypes. These subtypes have distinct RNA expression profiles and appear to be prognostic of clinical outcome.

104.••

Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152–65. doi:10.1016/j.ccr.2014.01.009. There are molecular subtypes of bladder cancer with distinct RNA expression profiles that appear to be prognostic of clinical outcome. The basal subtype is enriched for biomarkers reflective of immune infiltration, potentially suggesting a predictive role for immunotherapy.

Titel: Improving Systemic Chemotherapy for Bladder Cancer
verfasst von: Tracy L. Rose
Matthew I. Milowsky
Publikationsdatum: 01.05.2016
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 5/2016
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-016-0512-2

Springer Medizin

Improving Systemic Chemotherapy for Bladder Cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2016

Clinical Utility of Biomarkers in Localized Prostate Cancer

What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?

Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape

Vaginal Health During Breast Cancer Treatment

The Independent Effects of Strength Training in Cancer Survivors: a Systematic Review

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie